Department of Gastroenterology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, Shandong, China.
Department of Laboratory, Yidu Central Hospital of Weifang, Weifang, Shandong, China.
Bioengineered. 2022 Jan;13(1):1507-1517. doi: 10.1080/21655979.2021.2021063.
The objective of this study was to determine the expression levels of ASMTL-AS1 and miR-1270 in gastric cancer, and to explore whether ASMTL-AS1 and miR-1270 is associated with cancer prognosis and progression or not. ASMTL-AS1 and miR-1270 expression were quantified in gastric cancer tissues and adjacent normal tissues (n = 167) and cell lines. The potential of ASMTL-AS1 and miR-1270 as prognostic biomarkers was evaluated by the receiver operating characteristic (ROC) curve, Kaplan-Meier, and multivariate Cox regression analyses. The binding between ASMTL-AS1 and miR-1270 was verified by the Luciferase reporter assay and RNA pull-down assay. Functional roles of ASMTL-AS1/miR-1270 on cells were investigated in HGC-27 and NCI-N87 cells by MTS viability, Transwell migration, and Matrigel invasion assay. ASMTL-AS1 was significantly downregulated while miR-1270 was upregulated in gastric cancer tissues as compared with normal tissue and cell lines. According to the studies, ASMTL-AS1 and miR-1270 were related to unfavorable clinical parameters, such as the advanced TNM stage. Downregulated ASMTL-AS1 and upregulated miR-1270 were associated with reduced 5-year overall survival. Functional studies suggested that ASMTL-AS1 inhibits proliferation, migration, and invasion of HGC-27 and NCI-N87 cells by regulation of miR-1270. In summary, ASMTL-AS1 and miR-1270 are associated with poor prognosis of patients with gastric cancer. ASMTL-AS1 inhibited gastric cancer progression by regulating miR-1270. Therefore, ASMTL-AS1/miR-1270 may be a potential prognostic biomarker and novel strategy for gastric cancer targeted therapy.
本研究旨在测定胃癌中 ASMTL-AS1 和 miR-1270 的表达水平，并探讨其与癌症预后和进展的关系。我们对 167 例胃癌组织和相应的癌旁正常组织及细胞系进行了 ASMTL-AS1 和 miR-1270 的表达定量分析。通过接收者工作特征（ROC）曲线、Kaplan-Meier 分析和多因素 Cox 回归分析评估 ASMTL-AS1 和 miR-1270 作为预后生物标志物的潜力。通过荧光素酶报告实验和 RNA 下拉实验验证了 ASMTL-AS1 和 miR-1270 之间的结合。通过 MTS 细胞活力、Transwell 迁移和 Matrigel 侵袭实验，在 HGC-27 和 NCI-N87 细胞中研究了 ASMTL-AS1/miR-1270 对细胞的功能作用。与正常组织和细胞系相比，胃癌组织中 ASMTL-AS1 显著下调，miR-1270 上调。研究表明，ASMTL-AS1 和 miR-1270 与不良的临床参数有关，如晚期 TNM 分期。下调的 ASMTL-AS1 和上调的 miR-1270 与降低 5 年总生存率相关。功能研究表明，ASMTL-AS1 通过调控 miR-1270 抑制 HGC-27 和 NCI-N87 细胞的增殖、迁移和侵袭。总之，ASMTL-AS1 和 miR-1270 与胃癌患者的不良预后相关。ASMTL-AS1 通过调控 miR-1270 抑制胃癌的进展。因此，ASMTL-AS1/miR-1270 可能是一种有前途的胃癌预后生物标志物和新的靶向治疗策略。
